Molecular targets for treatment of inflammatory breast cancer
- 26 May 2009
- journal article
- review article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 6 (7), 387-394
- https://doi.org/10.1038/nrclinonc.2009.73
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like PhenotypeCancer Research, 2008
- Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapyBreast Cancer Research, 2007
- c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarraysBritish Journal of Cancer, 2007
- Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitroZeitschrift für Krebsforschung und Klinische Onkologie, 2006
- Targeting lymphangiogenesis to prevent tumour metastasisBritish Journal of Cancer, 2006
- Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitroAngiogenesis, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Distinct Molecular Signature of Inflammatory Breast Cancer by cDNA Microarray AnalysisBreast Cancer Research and Treatment, 2005
- An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survivalProceedings of the National Academy of Sciences, 2005
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002